Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.
about
Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysisInfluenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011Planning influenza vaccination programs: a cost benefit modelCost-effectiveness of gargling for the prevention of upper respiratory tract infections.Cost analysis of influenza vaccine administration in Fayette County, Kentucky, 2005-2007.Influenza and pneumococcal vaccination rates among Vietnamese, Asian, and non-Hispanic white Americans.Annual public health and economic benefits of seasonal influenza vaccination: a European estimateCost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.Influenza-associated hospitalizations, Singapore, 2004-2008 and 2010-2012.Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial.Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence.Health education and factors influencing acceptance of and willingness to pay for influenza vaccination among older adultsRacial and Ethnic Disparities in Influenza Vaccination among Adults with Chronic Medical Conditions Vary by Age in the United States.Pneumonia immunization in older adults: review of vaccine effectiveness and strategiesAntiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada.Influenza vaccination in patients with pulmonary sarcoidosis: efficacy and safety.Does influenza vaccination of older adult Medicare beneficiaries lower treatment costs for acute and chronic respiratory disease?The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients.Influvac, a trivalent inactivated subunit influenza vaccine.Issues in the economic evaluation of influenza vaccination by injection of healthy working adults in the US: a review and decision analysis of ten published studies.Annual all-cause healthcare costs among influenza patients with and without influenza-related complications: analysis of a United States managed care database.Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States.Influenza vaccination in the elderly.Cost-effectiveness of influenza vaccination of older adults in the ED setting.Economic benefits of sharing and redistributing influenza vaccines when shortages occurred.Concerns for low coverage of influenza vaccination in middle-aged adults.Cost-effectiveness of influenza control measures: a dynamic transmission model-based analysis.Cost-effectiveness of influenza vaccination of people aged 50-64 years in Australia: results are inconclusive.What determines influenza vaccination take-up of elderly Europeans?Cost-equivalence and Pluralism in Publicly-funded Health-care Systems.Older Human B Cells and Antibodies
P2860
Q28748161-0CF11C96-2564-4BAE-B33F-FBE6A208B997Q30351995-A02132C9-33CF-4A32-85C3-498664E9C6F7Q30419690-1A51564B-1084-46E7-8AF3-6B636368E061Q33393454-EBFBD5F2-F1D7-4B85-A0CF-98CF58107330Q33652834-76015A2E-2B84-4182-892C-14822CAC590CQ33822015-D6BA0608-5A50-4BDA-90B0-7FA4223C21E7Q34076633-BE07425B-BE01-438E-B139-A746C883D060Q34311593-598AF01D-822F-4BD7-B48F-8FDEAEA9DAD2Q34320911-56731898-372D-4761-B410-CDCE6064F34AQ34869353-6B608BD9-D2D5-48FC-8DE9-CDE8CF604E10Q35797338-4D1DCA38-5E64-4DA5-851E-7F7B39F41D6AQ35821963-C57A35CA-90B8-4AFB-AD35-314168CAB33CQ36247782-F33FCCF2-1A8F-4026-8FD0-55C69EEAC0CAQ36393396-6FF8C1C7-1B73-49FF-9F4E-FF9242AFFA56Q37055208-6E28CEDD-088A-4346-B858-4B604A351056Q37088022-BAC1A7C0-F27C-4514-A0E3-DFE7A963A205Q37167208-98938441-5C64-4EEB-96C3-83161BD776B6Q37597666-32B4BC6E-76EF-4804-9755-73B8589FAB90Q37812615-F6747ECD-51E6-4A87-A5CE-88E217CE961BQ37998520-AD7EBF67-15CE-4224-9B8E-FCB6587F3FC4Q38093109-1220A1CB-3CB1-41E6-B730-AD00581FC362Q39491859-DE5BA6E9-4675-416F-AF6B-70D55FAFAEFFQ40134515-5677C165-AC12-427E-B61F-6BF2E803CB93Q41470665-7529F426-84E0-4E8A-8F13-BC097ACBBB9DQ42656813-8873819C-4320-438C-B20A-6FB1313CD0E5Q42724024-6190409C-E7DE-4CDB-AA73-2935AAE24BF4Q43171156-7D0531AB-30E3-4C2B-BC43-8064DAF7332BQ45358167-AA13F187-A24D-40B2-832E-1B84A60D38F1Q45388994-09AB568A-6397-48B2-BA99-3C423B84C3EDQ48375575-58B65FEF-992D-4DC7-A443-D6F0355CDD94Q58045450-5005E6CF-9784-46AC-96A1-2E751C9B819B
P2860
Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Influenza vaccination health i ...... ged 50 to 64 and 65 and older.
@ast
Influenza vaccination health i ...... ged 50 to 64 and 65 and older.
@en
type
label
Influenza vaccination health i ...... ged 50 to 64 and 65 and older.
@ast
Influenza vaccination health i ...... ged 50 to 64 and 65 and older.
@en
prefLabel
Influenza vaccination health i ...... ged 50 to 64 and 65 and older.
@ast
Influenza vaccination health i ...... ged 50 to 64 and 65 and older.
@en
P2093
P1476
Influenza vaccination health i ...... aged 50 to 64 and 65 and older
@en
P2093
Ashley B Coffield
Leif I Solberg
Michael J Goodman
Nichol M Edwards
P356
10.1016/J.AMEPRE.2006.03.008
P577
2006-07-01T00:00:00Z